Scientists track cancer drug in blood to find best dose
NCT ID NCT07243483
Summary
This study aims to understand how the amount of the leukemia drug venetoclax in a patient's blood relates to how well the treatment works and its side effects. It will observe 100 adults with acute myeloid leukemia who are starting standard treatment with venetoclax and azacitidine. Researchers will collect extra blood samples to measure drug levels but will not change the patients' prescribed medical care.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Grenoble
RECRUITINGGrenoble, 38000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU de Saint-Étienne
RECRUITINGSaint-Etienne, 42100, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Leon Berard
RECRUITINGLyon, 69008, France
Contact Email: •••••@•••••
-
Hôpitaux Nord-Ouest - Villefranche-sur-Saône
RECRUITINGVillefranche-sur-Saône, 69400, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.